-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
December 26
Japanese biotech company PeptiDream announced that it has entered into a joint research and licensing agreement
with Eli Lilly for the creation and development of innovative peptide drug conjugates (PDCs).
PeptiDream
Unique cyclic peptides were identified that had high binding properties
to multiple targets selected by Eli Lilly using its own drug discovery development platform.
PeptiDream is responsible for the creation and optimization of peptides, Lilly
Responsible for the creation and optimization
of payloads.
The PDC created will be developed
by Lilly.
PeptiDream will receive an advance payment from Eli Lilly and possibly up to 12.
35
Payments for potential development and commercial milestones of 100 million US dollars (163 billion yen
).
The Company also has the right to collect royalties
based on sales after publication.
35 Payments for potential development and commercial milestones of 100 million US dollars (163 billion yen
).
PDC leader, PeptiDream, reached two agreements in three days last year, totaling $5.
7 billion
.
On July 27, 2021, PeptiDream and Takeda entered into a US$3.
5 billion collaboration agreement to expand their collaboration in the field of neurodegenerative disease therapeutics; On July 29, 2021, PeptiDream entered into a $2.
2 billion collaboration agreement with Alnylam to develop peptide-siRNA conjugates
.
PeptiDream's R&D pipeline
Original English text: _mstmutation="1" _msthash="220728" _msttexthash="2926391">
